Vantage Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Vantage Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-214,454	Closed	-$9.87M	–	66
2016 Q3	$9.87M	Buy	214,454 +10,654	+5%	+$556K	1.28%	28
2016 Q2	$10.2M	Buy	203,800 +138,200	+211%	+$7.36M	1.07%	37
2016 Q1	$3.51M	Buy	+65,600	New	+$3.85M	0.42%	44

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Vantage Investment Partners's TEVA Position: Q4 2016 in Review

Vantage Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 214,454 shares — an estimated $9.87M sold.

Vantage Investment Partners first reported a position in TEVA in Q1 2016 and held it in 3 quarters. The position peaked at $10.2M in Q2 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Vantage Investment Partners reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Vantage Investment Partners sold 214,454 Teva Pharmaceuticals shares in Q4 2016, an estimated $9.87M.
Vantage Investment Partners first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Vantage Investment Partners's Teva Pharmaceuticals position peaked at $10.2M in Q2 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Vantage Investment Partners's 13F filing for Q4 2016, filed 14 Feb 2017.